These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35849091)

  • 41. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
    Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
    Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?
    van der Marel J; Berkhof J; Ordi J; Torné A; Del Pino M; van Baars R; Schiffman M; Wentzensen N; Jenkins D; Quint WG
    Am J Surg Pathol; 2015 Apr; 39(4):496-504. PubMed ID: 25353286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genotype profile of HPV in ASC-H cytology and histologic follow-up-prevalence, distribution, and risk: A retrospective study of 1414 cases.
    Sun Y; Wang T; Zhong F; Starr D; Zeng X; Zhang H; Xiao J; Zhou X; Tao X; Zhao C
    Cancer Cytopathol; 2024 Jun; ():. PubMed ID: 38879864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Distribution of cervical lesions in high-risk HPV (hr-HPV) positive women with ASC-US: a retrospective single-center study in China.
    Wang Z; Gu Y; Wang H; Chen J; Zheng Y; Cui B; Yang X
    Virol J; 2020 Nov; 17(1):185. PubMed ID: 33228715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.
    Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC;
    PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of Cervical Neoplasia by Human Papillomavirus Testing in an Atypical Squamous Cells-Undetermined Significance Population: Results of the Becton Dickinson Onclarity Trial.
    Wright TC; Stoler MH; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper CK
    Am J Clin Pathol; 2019 Jan; 151(1):53-62. PubMed ID: 30189049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
    Stoler MH; Wright TC; Parvu V; Vaughan L; Yanson K; Eckert K; Karchmer T; Kodsi S; Cooper CK
    Gynecol Oncol; 2018 Jun; 149(3):498-505. PubMed ID: 29681462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extended Human Papillomavirus Genotype Distribution and Cervical Cytology Results in a Large Cohort of Chinese Women With Invasive Cervical Cancers and High-Grade Squamous Intraepithelial Lesions.
    Jiang W; Marshall Austin R; Li L; Yang K; Zhao C
    Am J Clin Pathol; 2018 May; 150(1):43-50. PubMed ID: 29746625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
    Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
    J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study.
    Siebers AG; Arbyn M; Melchers WJ; van Kemenade FJ; Vedder JE; van der Linden H; van Ballegooijen M; Bekkers RL; Bulten J
    Cancer Causes Control; 2014 Sep; 25(9):1141-9. PubMed ID: 24935226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interpreting a Diagnosis of Atypical Squamous Cells of Undetermined Significance in Cervical Cytology and its Association with Human Papillomavirus: A retrospective analysis of 180 cases in Kuwait.
    Kapila K; Balakrishnan M; Ali RH; Al-Juwaiser A; George SS; Mallik MK
    Sultan Qaboos Univ Med J; 2020 Nov; 20(4):e318-e323. PubMed ID: 33414936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening.
    Depuydt CE; Makar AP; Ruymbeke MJ; Benoy IH; Vereecken AJ; Bogers JJ
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):628-37. PubMed ID: 21297040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study.
    Thomsen LT; Dehlendorff C; Junge J; Waldstrøm M; Schledermann D; Frederiksen K; Kjaer SK
    Int J Cancer; 2016 Oct; 139(8):1839-50. PubMed ID: 27004595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
    Einstein MH; Martens MG; Garcia FA; Ferris DG; Mitchell AL; Day SP; Olson MC
    Gynecol Oncol; 2010 Aug; 118(2):116-22. PubMed ID: 20488510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of Human Papillomavirus Genotyping for Triage of Patients with Atypical Squamous Cells of Undetermined Significance by Cervical Cytology.
    Lee B; Suh DH; Kim K; No JH; Kim YB
    Anticancer Res; 2015 Jul; 35(7):4197-202. PubMed ID: 26124378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.